| Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates |
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.56 per share a year ago. |
zacks.com |
2025-05-08 22:10:35 |
Czytaj oryginał (ang.) |
| Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update |
HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update. |
globenewswire.com |
2025-05-08 20:01:00 |
Czytaj oryginał (ang.) |
| Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease |
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). |
globenewswire.com |
2025-05-05 20:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics to Present at Upcoming Investor Conferences |
HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: |
globenewswire.com |
2025-03-04 10:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 |
- CDX-622 inhibits SCF and TSLP-dependent inflammatory signatures in human skin - - Phase 1 study in healthy volunteers ongoing - |
globenewswire.com |
2025-03-03 10:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 |
- Greatly improved patient quality of life and reduced disease impact in patients with CSU and CIndU - - 82% of CSU patients reported that symptoms no longer had an impact on their quality of life at Week 52 - - 60% of CIndU patients reported that symptoms no longer had an impact on their quality of life at Week 12 - |
globenewswire.com |
2025-03-01 14:45:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates |
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to loss of $0.57 per share a year ago. |
zacks.com |
2025-02-27 20:31:09 |
Czytaj oryginał (ang.) |
| Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update |
HAMPTON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2024 and provided a corporate update. |
globenewswire.com |
2025-02-27 18:01:00 |
Czytaj oryginał (ang.) |
| Blueprint Medicines price target lowered by $11 at Wedbush, here's why |
Blueprint Medicines -3.19 (-3.52%) Celldex -2.21 (-8.33%) |
https://thefly.com |
2025-01-13 10:44:32 |
Czytaj oryginał (ang.) |
| Celldex Initiates Phase 2 Study of Barzolvolimab in Atopic Dermatitis |
HAMPTON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the Company has initiated a Phase 2 study of barzolvolimab in atopic dermatitis (AD) and that the study is actively enrolling patients. AD is one of the most common chronic inflammatory skin diseases, with a lifetime prevalence of up to 20% of the US population and a substantial impact on quality of life1. Mast cells are strongly implicated in all facets of AD pathophysiology and the fundamental processes that characterize AD, including epithelial barrier dysfunction, immune cell recruitment, neuroinflammation2 and multiple other mast cell-associated factors that correlate with disease severity. Activated mast cells are also found in increased numbers in lesional biopsies. Barzolvolimab is a humanized monoclonal antibody that specifically binds and blocks the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for the function and survival of the mast cell. |
globenewswire.com |
2024-12-19 10:01:00 |
Czytaj oryginał (ang.) |
| Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases |
HAMPTON, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company's Phase 1a study of CDX-622 in healthy volunteers. CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. |
globenewswire.com |
2024-11-20 10:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics to Present at Upcoming Investor Conferences |
HAMPTON, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: |
globenewswire.com |
2024-11-11 18:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates |
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.81 per share a year ago. |
zacks.com |
2024-11-06 20:30:32 |
Czytaj oryginał (ang.) |
| Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update |
HAMPTON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the third quarter ended September 30, 2024 and provided a corporate update. |
globenewswire.com |
2024-11-06 18:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market |
Celldex's primary revenue driver is Barzolvolimab, now in Phase 3 for CSU, targeting unmet needs in inflammatory diseases. Barzolvolimab has shown strong Phase 2 efficacy for CSU, though safety concerns may affect patient adherence. Celldex's solid cash position and long runway reduce dilution risks, supporting the continued development of its pipeline. |
seekingalpha.com |
2024-11-04 17:14:47 |
Czytaj oryginał (ang.) |
| Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria |
HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. |
globenewswire.com |
2024-10-26 21:43:00 |
Czytaj oryginał (ang.) |
| Celldex Announces Upcoming Late Breaking Oral Presentation of 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria at ACAAI 2024 |
HAMPTON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that 12 week results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD)—will be presented in a late breaking oral presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) Annual Scientific Meeting being held in Boston October 24-28, 2024. |
globenewswire.com |
2024-10-25 12:01:00 |
Czytaj oryginał (ang.) |
| CLDX Stock Down Despite Upbeat Long-Term Data From Urticaria Study |
Celldex stock falls due to safety concerns related to the treatment of urticaria patients with barzolvolimab in a phase II study, despite robust efficacy data. |
zacks.com |
2024-09-26 15:30:35 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024 |
- 71% of patients (150 mg Q4W) achieved complete response at Week 52 - - Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks - - Robust improvement across omalizumab-experienced/refractory/naïve disease - - Well tolerated through 52 weeks - - Enrollment to Global Phase 3 CSU trials underway - - Company to host webcast today at 12:00 pm ET/6:00 pm CEST - |
globenewswire.com |
2024-09-25 14:45:00 |
Czytaj oryginał (ang.) |
| Celldex Announces Upcoming Late Breaking Oral Presentation of 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV Congress 2024 |
HAMPTON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that an abstract describing 52 week results from the Company's Phase 2 clinical trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to antihistamines, including patients with biologic-refractory disease, has been accepted as a late breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 being held in Amsterdam on September 25-28, 2024. |
globenewswire.com |
2024-09-16 12:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics to Present at Upcoming Investor Conferences |
HAMPTON, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: |
globenewswire.com |
2024-09-12 20:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics (CLDX) Reports Q2 Loss, Tops Revenue Estimates |
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.65 per share a year ago. |
zacks.com |
2024-08-08 22:25:32 |
Czytaj oryginał (ang.) |
| Celldex Reports Second Quarter 2024 Financial Results and Provides Corporate Update |
HAMPTON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2024 and provided a corporate update. |
globenewswire.com |
2024-08-08 20:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics Presents Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Inducible Urticaria |
HAMPTON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive topline results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. CIndU is characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. |
globenewswire.com |
2024-07-29 20:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics Initiates Global Phase 3 Program for Barzolvolimab in Patients with Chronic Spontaneous Urticaria |
- EMBARQ-CSU1 and EMBARQ-CSU 2 will enroll more than 1800 patients suffering from CSU - - Studies include both biologic naïve and experienced patients - |
globenewswire.com |
2024-07-16 12:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics to Present at Jefferies Healthcare Conference |
HAMPTON, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 6th at 10:00 am ET. A webcast of the presentation will be available on the "Events & Presentations” page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event. |
globenewswire.com |
2024-06-04 20:01:00 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 |
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU - |
globenewswire.com |
2024-06-02 13:01:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Celldex (CLDX) Could Surge 87.27%: Read This Before Placing a Bet |
The mean of analysts' price targets for Celldex (CLDX) points to an 87.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-05-27 15:00:43 |
Czytaj oryginał (ang.) |
| Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Purchased by Swiss National Bank |
Swiss National Bank boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) by 9.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 97,000 shares of the biopharmaceutical company’s stock after acquiring an additional 8,700 shares during the period. Swiss National Bank owned about 0.21% of Celldex Therapeutics worth $3,847,000 at the end of the most recent quarter. Several other hedge funds and other institutional investors have also added to or reduced their stakes in CLDX. Teacher Retirement System of Texas increased its stake in shares of Celldex Therapeutics by 4.8% during the third quarter. Teacher Retirement System of Texas now owns 11,400 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 522 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 805 shares in the last quarter. New York State Common Retirement Fund raised its holdings in shares of Celldex Therapeutics by 3.6% during the third quarter. New York State Common Retirement Fund now owns 23,780 shares of the biopharmaceutical company’s stock valued at $654,000 after acquiring an additional 821 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of Celldex Therapeutics by 4.6% in the fourth quarter. Fisher Asset Management LLC now owns 21,492 shares of the biopharmaceutical company’s stock valued at $852,000 after acquiring an additional 954 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Celldex Therapeutics by 3.8% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,258 shares of the biopharmaceutical company’s stock worth $1,041,000 after acquiring an additional 962 shares during the last quarter. Celldex Therapeutics Trading Down 4.3 % Shares of CLDX opened at $38.21 on Monday. Celldex Therapeutics, Inc. has a 12-month low of $22.11 and a 12-month high of $53.18. The firm has a market capitalization of $2.52 billion, a P/E ratio of -13.41 and a beta of 1.60. The firm has a 50-day moving average price of $40.41 and a 200 day moving average price of $37.93. Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.19. The business had revenue of $4.13 million during the quarter, compared to analysts’ expectations of $1.20 million. Celldex Therapeutics had a negative net margin of 2,385.57% and a negative return on equity of 29.55%. Equities research analysts predict that Celldex Therapeutics, Inc. will post -2.32 earnings per share for the current fiscal year. Analyst Ratings Changes A number of research analysts have weighed in on CLDX shares. Guggenheim raised their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, February 27th. Cantor Fitzgerald restated an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, May 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $66.00. View Our Latest Stock Analysis on CLDX Celldex Therapeutics Profile (Free Report) Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. See Also Five stocks we like better than Celldex Therapeutics How to Invest in the FAANG Stocks MarketBeat Week in Review – 5/13 – 5/17 Dividend Screener: How to Evaluate Dividend Stocks Before Buying Take-Two Interactive Software Offers 2nd Chance for Investors Golden Cross Stocks: Pattern, Examples and Charts Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook |
https://www.defenseworld.net |
2024-05-20 08:43:11 |
Czytaj oryginał (ang.) |